DAY TWO
8:30 am Morning Refreshments
9:20 am Chair’s Opening Remarks
Translating Novel Obesity Therapies into Practice Using Clinical Insights to Improve Patient Personalisation for More Effective Treatment
9:30 am Building Precision Medicine-Based Approaches to Address End Organ Fibroinflammation in Metabolically Challenged Individuals
Synopsis
- Building precision medicine approaches to address end-organ damage in metabolically challenged patients provides the advantage of targeting the root cause of the disease, which leads to personalized, more effective therapies
- Focusing on fibroinflammation offers the advantage of addressing the specific pathological process driving organ failure, which results in improved clinical outcomes and better long-term quality of life
- Developing a multi-faceted therapeutic strategy provides the advantage of leveraging multiple points of intervention to restore metabolic homeostasis, which leads to more durable treatment effects for complex chronic diseases
10:00 am Connecting Directly with Patients: Understanding Weight Management Journeys Through Continuous Multimodal Real-World Data
Synopsis
- EHR and claims data are essential to real-world evidence, but they capture only fragments of the patient journey. Evidation enables a longitudinal, multimodal approach to real-world data collection by maintaining a continuous, consented connection with individuals over time
- In this case study, Evidation applied this approach to real-world data collection by maintaining a continuous, consented connection with a cohort of over 150,000 individuals managing their weight including more than 10,000 GLP-1 users
- Through this connection, Evidation collected patient-reported outcomes, sensorbased behavioral data, and social determinants of health, with the ability to enrich these data through linkage to EHRs, claims, and biospecimens. This patient centric model reveals how and why individuals initiate, sustain, or discontinue treatment, enabling earlier signal detection, more targeted study designs, and stronger realworld interpretation
10:30 am Morning Break & Networking
Refining Dosing Regimens to Support Patient Commitment & Amplify Therapeutic Impact in Real-World Settings
11:00 am Roundtable Discussion: Implementing Flexible Dosing Schedules for Accommodating Patient Lifestyles to Improve Treatment Consistency for Better Long-Term Results
Synopsis
- Offering once-weekly or monthly dosing options for reduced administration burden to enhance patient convenience for improved compliance
- Developing personalized dosing algorithms for individual metabolic profiles to optimize therapeutic response for maximized weight loss efficacy
- Providing patient support programs for education and adherence coaching to address barriers to compliance for sustained treatment engagement
12:00 pm Preclinical Development of Oral Small Molecule GLP-1 Agonists: Challenges & Solutions
Synopsis
- Screening paradigms for in vitro cell efficacy, ADME and DMPK
- Validating appropriate in vivo pharmacodynamic models
- In vivo efficacy and safety assessments: early and often
- Clinical Candidate nomination: data from Ambrosia’s proprietary program to be presented
12:30 pm Advancing Obesity Clinical Trials with Quantitative MRI: Multi-Organ and Body Composition Imaging
Synopsis
- Beyond weight loss: Using quantitative MRI to track fat distribution and body composition changes in obesity trials
- Multi-organ insights: Leveraging MRI to phenotype metabolic diseases by assessing liver, kidney, heart, and muscle health
- Enhancing trial outcomes: Integrating quantitative MRI with traditional biomarkers for deeper patient insights and optimized clinical trial design
12:40 pm Lunch
Developing Tolerability-Driven Therapies to Increase Patient Comfort & Sustain Treatment Engagement/center>
1:40 pm Next-Generation Obesity Therapeutics: Long-Acting Antibodies for Improved Quality of Weight Loss
Synopsis
- Evaluating how the long-acting nature of next-generation antibodies improves patient adherence and convenience, providing a clear advantage in sustaining long-term weight loss and ensuring superior patient outcomes
- Discussing how these antibodies are being engineered for improved tolerability and reduced side effects, offering a clear benefit in enhancing patient comfort and ensuring more durable treatment engagement
- Analyzing how these long-acting therapies are being designed to not only reduce body weight but also improve body composition, providing a distinct advantage in promoting a higher quality of weight loss with a focus on muscle preservation and metabolic health
2:10 pm Designing a Next-Generation Therapeutic with Unmatched Tolerability to Drive Long-Term Patient Continuation
Synopsis
- Mitigating common side effects through targeted drug design and optimized delivery methods to reduce GI distress and improve the overall patient experience
- Utilizing advanced formulation science to ensure consistent drug exposure and minimize dose-related adverse events for a safer, more predictable therapeutic profile
- Integrating behavioral insights into the development process to create a treatment that aligns with patient lifestyles and maximizes adherence beyond a clinical setting
2:40 pm Panel Discussion: Synthesizing Breakthrough Discoveries to Chart Future Directions for Accelerating Therapeutic Innovation for Broader Patient Impact
Synopsis
- Integrating cross-disciplinary insights for comprehensive understanding to identify synergistic opportunities for more effective drug development strategies
- Forecasting emerging trends and technologies for proactive research planning to anticipate future challenges for sustainable therapeutic pipelines
- Fostering global collaborations and partnerships for shared knowledge and resources to expedite clinical translation for faster patient access to novel treatments